Skip to main content

Table 5 Pharmacokinetic parameters of liraglutide following intravenous (IV, 0.05 mg/kg) and subcutaneous (SC, 1 mg/kg) injection in rats (mean ± SD, n = 5)

From: Pharmacokinetics and brain distribution of the therapeutic peptide liraglutide by a novel LC–MS/MS analysis

 

IV (n = 5)

SC (n = 5)

Dose (mg/kg)

0.05

1.00

t1/2 (h)

3.67 ± 0.40

3.55 ± 0.51

C0 or Cmax (ng/mL)

822.08 ± 227.19

669.64 ± 186.57

Tmax (h)*

3.00 (2.00–6.00)

AUCall (ng·h/mL)

3429.30 ± 875.27

9166.62 ± 2465.16

AUCinf (ng·h/mL)

3505.33 ± 815.04

9223.30 ± 2417.73

CL or CL/F (mL/min/kg)

0.25 ± 0.06

1.92 ± 0.52

Vss (mL/kg)

73.12 ± 20.68

Bioavailability

13.16%

  1. *Data were presented as the median (minimum–maximum)